Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00729404
First received: August 4, 2008
Last updated: February 19, 2014
Last verified: February 2014
  Purpose

Investigation of two transdermal hormone patch formulations for contraception regarding inhibition of ovulation over a period of 3 treatment cycles in healthy young female volunteers


Condition Intervention Phase
Contraception
Ovulation Inhibition
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter, Open-label, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg EE and Either 1.05 or 2.1 mg GSD in Healthy Young Female Vol. Over a Period of 3 Treatment Cycles

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • The primary efficacy variable will be the proportion of volunteers with ovulation in at least one of the treatment cycles 2 and 3. [ Time Frame: 4 month ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Assessment of ovarian activity during treatment cycle2 and 3 (Hoogland score) [ Time Frame: 4 month ] [ Designated as safety issue: Yes ]
  • Course of gonadotropins (FSH, LH, P, E2) [ Time Frame: 4 month ] [ Designated as safety issue: Yes ]
  • Endometrial thickness [ Time Frame: 4 month ] [ Designated as safety issue: Yes ]
  • Follicle size [ Time Frame: 4 month ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics of EE, GSD and SHBG in treatment cycles 2 and 3 [ Time Frame: 4 month ] [ Designated as safety issue: Yes ]

Enrollment: 13
Study Start Date: August 2008
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Ethinylestradiol/Gestodene (BAY86-5016)
transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
Experimental: Arm 2 Drug: Ethinylestradiol/Gestodene (BAY86-5016)
transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles

Detailed Description:

Study was suspended due to inconclusive toxicology findings regarding the used patch formulation to be clarified prior to re-start of the study.

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Signed informed consent,
  • BMI: 18 - 30 kg/m²,
  • Healthy female volunteers,
  • Age 18-35 years (smoker not older than 30 years, inclusive),
  • Ovulatory pre-treatment cycle, at least 3 month since delivery,
  • Abortion or lactation before the first screening examination,
  • Willingness to use non-hormonal methods of contraception during entire study

Exclusion Criteria:

  • Contraindications for use of combined (estrogen/gestodene) contraceptive (e.g. history of venous/arterial thromboembolic disease
  • Regular intake of medication other than OCs
  • Clinically relevant findings (blood pressure, physical and gynaecological examination, laboratory examination)
  • Anovulatory pre-treatment cycle
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00729404

Locations
Germany
Berlin, Germany, 10115
Berlin, Germany, 13342
Berlin, Germany, 10707
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT00729404     History of Changes
Other Study ID Numbers: 91558, 2008-001198-13
Study First Received: August 4, 2008
Last Updated: February 19, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Bayer:
Female Contraception
Ovulation Inhibition

Additional relevant MeSH terms:
Ethinyl Estradiol
Femovan
Gestodene
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Combined
Contraceptives, Oral, Synthetic
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Progestins
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014